** Shares of medtech firm Glaukos GKOS.N fall 11.2% to $139.7 premarket
** Co on Thursday posted Q4 net loss of $22.2 mln, vs Wall Street estimate of $20.8 mln loss, as per data compiled by LSEG
** GKOS reported Q4 revenue of $105.5 mln, vs est. of $100.7 mln
** Co forecast 2025 sales in the range of $475 million to $485 million compared with expectation of $479.8 mln
** GKOS's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve
** Stock has risen 75.7% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。